Specialty Pharmacy

David Lassen, chief clinical officer at Prime Therapeutics, discusses changes in store for the field of specialty pharmacy in the coming years.

Additional benefit from dasabuvir and combination of ombitasvir/paritaprevir/ritonavir found in pretreated genotype 1b hepatitis C patients without cirrhosis.

Research may help to target which patients will respond to specific chemotherapy drugs.

Inhibiting oxygen sensor leads to a reduced spread of breast cancer throughout the body.

Majority of participants experienced no spontaneous joint bleeding episodes.

Hepatitis C drugs with high cure rates create new dilemma for people in need of transplantation.

Patient experiences complete remission after treatment with 2 immunotherapies.

Patient who make multiple trips to their general practitioner before getting a diagnosis are more likely to respond negatively to other aspects of their care.

Roche is seeking FDA premarket approval of its companion diagnostic test for AstraZeneca's investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation.

Salt found to influence immune cells that cause the disease.

Nivolumab shows promise in patients whose disease progressed after ipilimumab and BRAF inhibitor therapy.

Catch up with the latest developments in cancer research.

Weight cycling may influence the biological processes that can lead to cancer.

Process improves the accuracy of cancer treatments.

High cost of research and development causes less investment by pharmaceutical firms.

A look back at the top stories of the week on Specialty Pharmacy Times.

Researchers predict the progression of the cancer based on its expression of IL13RA2.

Senate draft of the 2016 NDAA includes copay hikes for brand-name and non-formulary medications.

Researchers explore the use of probiotics to alter communication between brain and immune system.

Updated information includes drug-drug interaction.

Active surveillance increases in prevalence.

Despite inducing anti-HIV antibodies, vaccine in HVTN 505 trial still not protective.

Medication will be used as an add-on maintenance therapy in patients aged 12 years and older.

Caregivers can have trouble differentiating ulcerative colitis from Crohn's disease and inflammatory bowel disease.

Pharmacists in Washington State can no longer cite religion to refuse to fill a prescription.

Diabetics are at greater risk for viral and bacterial infection compared with the remainder of the population.

One confirmed case and one probable case of definite progressive multifocal leukoencephalopathy reported in patients taking Gilenya for MS.

Study finds significant barriers to health care access, including stigmatization.